Abbreviations: HD = Hodgkin disease; MDS = myelodysplastic syndrome; MM = multiple myeloma; NHL = non Hodgkin lymphoma.
Different studies have attempted to identify the best strategy to prevent GvHD 1-7 without hampering GvL. We previously compared the combination of sirolimus (SRL) plus tacrolimus (TKR) with Cyclosporine and mofetil mycophenolate in the setting of unrelated donor (UD) reduced intensity conditioning (RIC), 3 and found significantly better outcomes for SRL/TKR in terms of chronic GvHD (55 vs 88%), non-relapse mortality (NRM) (18 vs 38% at 2 years) and overall survival (OS) (72 vs 44%). With this background the use of SRL/TKR has been widespread for alloRIC, regardless of donor type.
We report a total of 122 patients who underwent alloRIC from October 2008 to June 2013 in 6 Spanish centers, with SRL/TKR as GvHD prophylaxis for alloRIC. Two RIC regimens were used, as previously detailed:
3,4 fludarabine plus melphalan or busulfan for lymphoid or myeloid malignancies, respectively. Data on doses and schedule of SRL/TKR have also been described. 3 Primary end points of this study were cumulative incidences (Cum.Inc) of GvHD, NRM, relapse, OS and event-free survival (EFS). The Cum.Inc was computed with the cmprsk package for R 2.14.0 software (R-Development-Core-Team, http://www.R-project.org/). OS and EFS were estimated by the Kaplan − Meier method.
Patients' characteristics are shown in Table 1 . Remarkably, the most frequent donor type was unrelated (75.4%) and HLA mismatched at A,B,C or DRB1 was present in 16.5%. Fifty percent of the patients were not in remission at the time of transplant. Cum.Inc of grades 2-4 and 3-4 acute GvHD at 100 days were 43% (35-52.5) and 7.4%, 4-14 whereas 1 and 3 years Cum.Inc of chronic GvHD was 47% (38.5-57.8) and 76% (67-86), respectively (29.5% (22-40) and 51% (41-63.7) for extensive cGvHD). This is in contrast to the data reported by Pidala et at., 8 who described an incidence of 24% moderate/severe cGvHD among patients receiving SRL/TRK vs 64% among patients receiving TKR/MTX. These differences could be attributed, at least in part, to the different donors type (50% of matched related donors in the study by Pidala versus 75.4% of UDs in the current study). More recently, the first randomized trial published up to now comparing SRL/TKR plus MTX versus TKR/MTX for alloRIC in patients diagnosed with lymphoma 9 did not find significant differences in terms of chronic GvHD but a lower risk of grades 2-4 acute GvHD for patients receiving SRL/TKR plus MTX (9 vs 25%, P: 0.01). In order to decrease the risk of cGvHD among patients receiving SRL/TKR preserving the graft versus tumor effect, additional strategies have been explored, such as the combination with cyclophosphamide or bortezomib. 10, 11 ATG has also been used in combination with SRL/TKR but a potential higher risk of infectious complications or relapses must be taken into account. 12 In the current study, 90 patients (76%) reached CR, 2 (2%) showed partial response and stable or progressive disease was observed in 20 patients (17%, non evaluable, n = 7 patients). Cum.Inc of relapse at 1 and 3 years was 11.5% (7-19.2) and 21.6% (14-32.7), respectively. Bearing in mind that at least half of the patients were not in remission at the time of transplant, these results are encouraging.
A total of 30 patients died (24.6%) at last the follow-up. Cum.Inc of NRM was 5.3% (2.4-11.5) at 100 days and 11.6% (CI = 6.9-19.4) at 1 year. The causes of NRM were GvHD in 7 cases (41% of all deaths), infectious complications in 6 cases (35%), multiorgan failure in 1 case, veno-occlusive disease in 1 case, graft failure in 1 case and alveolar hemorrhage in 1 case. In addition, as far as the toxicity profile is concerned we found a low incidence of entohelial damage related toxicity (3.3% for veno-occlusive disease and 11.5% for thrombotic microangiopathy), although they could be underestimated, bearing in mind the retrospective nature of the study. Anyway they did not affect the OS in our series. Some issues such an earlier start data for SRL at a lower dose than previously reported, [5] [6] [7] together with a strict monitoring of SRL and TKR levels may have an impact on a low rate of these toxicities. 13 With respect to infectious complications, probable or proven fungal infections occurred in 16 patients (13.1%). It is of note that broad-spectrum antifungal prophylaxis were not used and this rate was not higher than that described in other reports which used broad antifungal prophylaxis.
14 Also, 42 patients (34%) had CMV infection whereas CMV disease occurred in just 2 cases (1.6%).
With a median follow up of 23.5 months among patients alive, EFS and OS at 3 years were 54% (CI = 41.5-63.3) and 68.5% (CI = 57.3-77.3), respectively ( Figure 1 ). Considering that more than two thirds of the patients underwent unrelated donor (URD) transplantation and almost half of them had measurable disease, survival rates are unexpectedly high in this multicenter study, in line with our previous and others' experience. 3, 5 In the current study, patients diagnosed with lymphoma (n:39) displayed a worse outcome as compared to the rest, with a higher NRM: 23.6% (CI = 18.8-29.6) vs 14.3% (CI = 8.6-23.8) at 1 year, P = 0.005, and a trend towards a lower OS: 53.6% vs 74.8% at 3 year, P = 0.1. In the randomized study by Armand's et al. 9 only patients diagnosed with lymphoma were included and they did not observe differences in terms of OS, disease free survival (DFS) or NRM depending on the GvHD prophylaxis used, although some relevant differences between both studies must be pointed out, such as the conditioning regimen used (FluMel in our series in patients with lymphoma vs FluBu in Armand's study). 9, 15 It must be emphasized that the current results should not be extrapolated to the myeloablative transplant setting or other type of conditionings not explored in the current study. Remarkably, another prospective trial failed to demonstrate superiority of the combination of SRL/TKR as compared to TKR/MTX in the myeloablative setting 5, 7 even though busulphan plus cyclophosphamide (BuCy) was not used in order to avoid the increased risk of microangiopathy displayed by these patients. In addition, the trial reported by Cutler et al. 7 only included patients undergoing matched related donor transplant and it is possible that, as pointed out by the authors, the inclusion of higher-risk subjects, that is, those undergoing UD transplants, is required to demonstrate a benefit on the use of SRL/TKR.
In conclusion, in the current study the combination of SRL plus TKR was well tolerated in the setting of RIC and, in this multicenter study, allowed to obtain a 3-year OS in the range of 70% in a high-risk series of patients. Accordingly, it might be considered an appropriate backbone for additional strategies in this setting. Letter to the Editor
